Bioengineering & Organoids platform
Tissue-explant-on-chip system. Image copyright: Francois Signorino-Gelo and Marzena Walaszczyk (PTBET).
Our vision and mission
Welcome to the Bioengineering and Organoids Technology (BET) platform, an innovative initiative from EPFL, Unil, CHUV, UniGe, HUG and Ludwig Institute, housed in the cutting-edge AGORA Cancer Research Center in Lausanne.
The BET platform is here to provide you with access to cutting-edge technologies and expertise, to facilitate engagement with the clinical and translational landscape, and to accelerate the development of innovative assays, technologies, and approaches. We actively support researchers towards the development and deployment of these novel technologies and contribute to pushing the boundaries of scientific exploration.
Our capabilities revolve around three main axes:
1_ Organoids and advanced multicellular models: Our platform provides the necessary expertise and resources for the culture and development of organoids and advanced multicellular models, fostering the creation of more accurate and reliable in vitro models systems.
2_ Rapid micro-fabrication and prototyping: We offer state-of-the-art facilities for the efficient production and testing of microfluidic devices, biomaterials, and organ-on-chip systems, enabling you to rapidly iterate and refine your designs.
3_ Specialized instrumentation: We offer specialized instrumentation, including high-throughput microfluidics, assay automation, and high-content imaging, to support the development and implementation of custom experiments tailored to your specific research goals.
Join us at the BET platform and become part of a vibrant community where collaboration, innovation, and impactful research thrive. Together, we can revolutionize translational bioengineering and make a lasting impact on scientific discovery.
